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Human parainfluenza virus type 1 (HPIV1) is a significant cause of pediatric respiratory disease in the
upper and lower airways. An in vitro model of human ciliated airway epithelium (HAE), a useful tool for
studying respiratory virus-host interactions, was used in this study to show that HPIV1 selectively infects
ciliated cells within the HAE and that progeny virus is released from the apical surface with little apparent
gross cytopathology. In HAE, type I interferon (IFN) is induced following infection with an HPIV1 mutant
expressing defective C proteins with an F170S amino acid substitution, rHPIV1-CF170S, but not following
infection with wild-type HPIV1. IFN induction coincided with a 100- to 1,000-fold reduction in virus titer,
supporting the hypothesis that the HPIV1 C proteins are critical for the inhibition of the innate immune
response. Two recently characterized live attenuated HPIV1 vaccine candidates expressing mutant C
proteins were also evaluated in HAE. The vaccine candidates, rHPIV1-CR84G/170HNT553ALY942A and
rHPIV1-CR84G/170HNT553AL1710-11, which contain temperature-sensitive (ts) attenuating (att) and non-ts
att mutations, were highly restricted in growth in HAE at permissive (32°C) and restrictive (37°C)
temperatures. The viruses grew slightly better at 37°C than at 32°C, and rHPIV1-CR84G/170HNT553ALY942A
was less attenuated than rHPIV1-CR84G/170HNT553AL1710-11. The level of replication in HAE correlated
with that previously observed for African green monkeys, suggesting that the HAE model has potential as
a tool for the preclinical evaluation of HPIV1 vaccines, although how these in vitro data will correlate with
vaccine virus replication in seronegative human subjects remains to be seen.
Human parainfluenza viruses (HPIVs) are enveloped, non-
segmented, single-stranded, negative-sense RNA viruses be-
longing to the family Paramyxoviridae. This group of viruses
includes HPIV serotype 1 (HPIV1), HPIV2, and HPIV3,
which collectively are the second leading cause of pediatric
respiratory hospitalizations following respiratory syncytial vi-
rus (RSV) infections (25, 36). HPIV1 is responsible for ap-
proximately 6% of pediatric hospitalizations due to respiratory
tract disease (25). Clinical manifestations range from mild
disease, including rhinitis, pharyngitis, and otitis media, to
more severe disease, including croup, bronchiolitis, and pneu-
monia (11, 22, 23, 25, 32, 46). Currently, licensed vaccines for
the prevention of disease caused by any HPIV serotype are not
available.
The HPIV1 genome is 15,600 nucleotides in length and
contains six genes in the order 3-N-P/C-M-F-HN-L-5 (40).
Each gene encodes a single protein, with the exception of the
P/C gene, which encodes the phosphoprotein, P, in one open
reading frame (ORF) and up to four accessory C proteins, C,
C, Y1, and Y2, in a second ORF. The C proteins initiate at
four separate translational start codons in the C ORF in the
order C, C, Y1, and Y2 and are carboxy coterminal (25),
although it is unclear whether the Y2 protein is actually ex-
pressed during HPIV1 infection (45). C proteins are expressed
by viruses of the genera Respirovirus, Morbillivirus, and Heni-
pavirus but not by viruses of the genera Rubulavirus and Avu-
lavirus. The C proteins of Sendai virus (SeV), a member of the
Respirovirus genus and the closest homolog of HPIV1, are
perhaps the most extensively studied and have been shown to
have multiple functions, including the inhibition of the host
innate immune response by acting as interferon (IFN) antag-
onists (16, 20, 26).
To date, the HPIV1 C proteins have not been extensively
studied, although recent studies provide evidence for a role for
these proteins in the evasion of the host innate immune re-
sponse. In A549 cells, a human lung adenocarcinoma epithelial
cell line, it was previously shown that type I IFN production
was not detected during infection with wild-type HPIV1
(HPIV1 wt) (59). Since type I IFN was induced during infec-
tion of A549 cells with a recombinant HPIV1 (rHPIV1) mu-
tant with C proteins bearing an F170S amino acid substitu-
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tion (rHPIV1-CF170S), a role for the C proteins as antagonists of
the type I IFN response was suggested (59). This function was
demonstrated to affect the innate immune response at the level
of type I IFN induction and IFN signaling (59). Another study
independently confirmed the role of the HPIV1 C proteins as
antagonists of the type I IFN response, demonstrating that
HPIV1 infection could inhibit STAT1 nuclear translocation
and overcome an established IFN-induced antiviral state in
MRC-5 human lung fibroblast cells and, furthermore, that
HPIV1 C-protein expression was sufficient to inhibit STAT1
nuclear translocation in A549 cells (8). In contrast to the first
study, the latter study demonstrated that type I IFN was in-
duced during infection of MRC-5 cells with HPIV1 wt (8),
which suggests that the inhibition of type I IFN induction is cell
type specific. Therefore, further studies are required to better
define the host IFN response in relevant cell types that are
infected during HPIV1 infection in humans. This is particularly
important because vaccine candidates with defective C pro-
teins are being prepared for clinical trials, as described below.
In vitro models of the human airway epithelium (HAE) that
closely mimic the morphological and physiological features of
the HAE in vivo are now well characterized (43, 67). These
models use freshly isolated human airway cells grown at an
air-liquid interface to generate a differentiated, pseudostrati-
fied, mucociliary epithelium that bears close structural and
functional similarity to HAE in vivo. Such models were previ-
ously used to demonstrate that paramyxoviruses such as RSV
and HPIV3 preferentially infect ciliated cells, suggesting that
these cells play a critical role in paramyxovirus replication and
pathogenesis in the respiratory tract (66, 67). In addition, HAE
models have been used to evaluate the attenuation of RSV
vaccines (61).
In the present study, we attempted to validate the in vitro
HAE model for HPIV1 infection. In order to do this, we first
evaluated the levels of replication, cell tropism, and gross
pathogenic effects of HPIV1 wt infection in HAE in an exper-
imental setting (including infection with a low multiplicity of
infection [MOI] and multicycle growth) that mimics virus in-
fection of the lower conducting cartilaginous airways of hu-
mans. Second, we evaluated the abilities of HPIV1 wt and
rHPIV1-CF170S mutant viruses to induce a type 1 IFN response
and examined the role of the induced IFN in restricting the
replication of HPIV1 in HAE cultures. In this way, the phe-
notypes previously associated with HPIV1 C mutants in cell
culture and in vivo in African green monkeys (AGMs) were
characterized in HAE cultures. These data suggested that
HPIV1 replication in the HAE model is predictive of HPIV1
infection and growth in vivo. Therefore, we next compared the
levels of attenuation of replication of two HPIV1 vaccine can-
didates in the airways of AGMs (2, 3, 34, 39) to that seen in the
HAE model. This comparison revealed that the levels of rep-
lication of the two vaccine candidates are similar in HAE cells
and in AGMs and, in addition, unexpectedly revealed the abil-
ity of the HAE system to detect an attenuating effect of mu-
tations in genes such as L that are not revealed by other in vitro
cell culture systems. The ability of the HAE model to predict
the attenuation of vaccine viruses for humans will be further
analyzed once clinical studies of humans are completed, and
the levels of replication of the vaccine candidates in AGMs, in
HAE cells, and in humans can be compared. Clinical studies
for one of the vaccine candidates, rHPIV1-CR84G/170
HNT553A LY942A, are currently in progress. The current find-
ings suggest that HAE cultures are a useful model system for
the preclinical evaluation of live attenuated HPIV vaccines.
MATERIALS AND METHODS
Cells and viruses. Human airway tracheobronchial epithelial cells were iso-
lated from airway specimens from patients without underlying lung disease,
provided by the National Disease Research Interchange (Philadelphia, PA), or
as excess tissue following lung transplantation under University of North Caro-
lina at Chapel Hill (UNC) Institutional Review Board-approved protocols by the
UNC Cystic Fibrosis Center Tissue Culture Core. Primary cells derived from
single-patient sources were expanded on plastic to generate passage 1 cells and
plated at a density of 3  105 cells per well on permeable Transwell-Col (12-
mm-diameter) or 2  105 cells per well on permeable Millicell (12-mm-diameter)
supports. HAE cultures were grown in custom medium with the provision of an
air-liquid interface for 4 to 6 weeks to form differentiated, polarized cultures that
resemble in vivo pseudostratified mucociliary epithelium, as previously described
(43). LLC-MK2 cells (ATCC CCL 7.1) and HEp-2 cells (ATCC CCL 23) were
maintained in Opti-MEM I (Gibco-Invitrogen, Inc., Grand Island, NY) supple-
mented with 5% fetal bovine serum and gentamicin sulfate (50 g/ml). Vero cells
(ATCC CCL-81) were maintained in Opti-PRO SFM (Gibco-Invitrogen, Inc.)
supplemented with 50 g/ml gentamicin sulfate and 4 mM L-glutamine. Media
used for HPIV1 propagation and infection in LLC-MK2 cells contained 1.2%
TrypLESelect, a recombinant trypsin (Gibco-Invitrogen, Inc.), without fetal bo-
vine serum, in order to activate the HPIV1 F protein.
Biologically derived HPIV1 wt strain Washington/20993/1964, the parent for
the recombinant virus, was isolated previously from a clinical sample in primary
AGM kidney cells and passaged two additional times in primary AGM kidney
cells (37) and once in LLC-MK2 cells (3). This preparation has a wild-type
phenotype in AGMs, was previously designated HPIV1LLC1 (3), and will be
referred to here as HPIV1 wt or its recombinant version, rHPIV1 wt. The
construction of the rHPIV1 mutants rHPIV1-CF170S, rHPIV1-CR84G/170
HNT553ALY942A, and rHPIV1-CR84G/170HNT553AL1710-11 was described previ-
ously (2, 4). Each of the mutant viruses is named according to the mutations that
it contains: CF170S refers to the indicated amino acid substitution in the C protein
and confers a non-temperature-sensitive (ts) attenuation (att) phenotype; C170
refers to a six-nucleotide deletion spanning codon 170 in C and confers a non-ts
att phenotype; CR84G and HNT553A refer to amino acid substitutions in C and
HN that, in combination, confer a non-ts att phenotype but individually have no
attenuation phenotype; LY942A refers to the indicated amino substitution in L
and confers a ts att phenotype; and L1710-11 has the deletion of the indicated
residues in L and confers a ts att phenotype. The CF170S mutation is silent in the
overlapping P protein. The rHPIV1-CF170S mutant tested both here and in
previous studies contains the nonattenuating HNT553A mutation (2, 59). Since
previous studies referred to this virus simply as rHPIV1-CF170S (2, 59), we will
employ the same nomenclature here for the purpose of comparison. Purified
virus stocks were obtained by infecting LLC-MK2 cells and purifying the super-
natant by centrifugation and banding in discontinuous 30% to 60% (wt/vol)
sucrose gradients, steps designed to minimize contamination by cellular factors,
especially IFN. Purification also removes exogenous trypsin from the virus prep-
aration; however, since the viruses were prepared in trypsin medium, it is likely
that the F proteins of the inoculum virus were cleaved. The vesicular stomatitis
virus (VSV) used was a recombinant VSV-green fluorescent protein (GFP),
originally obtained from John Hiscott (55). Stocks of VSV were propagated in
Vero cells and sucrose purified, as indicated above.
Virus titers in samples were determined by 10-fold serial dilution of virus in
96-well LLC-MK2 monolayer cultures using 2 to 4 wells per dilution. After 7 days
at 32°C, infected cultures were detected by hemadsorption with guinea pig
erythrocytes, as described previously (52). Virus titers are expressed as log10 50%
tissue culture infectious doses (TCID50) per ml. VSV stock titers were deter-
mined by plaque assay on Vero cells under 0.8% methyl cellulose overlay.
Viral inoculation of HAE. HAE cultures were washed with phosphate-buffered
saline (PBS) to remove apical surface secretions, and fresh medium was supplied
to the basolateral compartments prior to infection. HPIV1s were applied to the
apical surface of HAE for inoculation at a low-input MOI (0.01 TCID50/cell) or
a high MOI (5.0 TCID50/cell), and VSV was applied to the basolateral surface at
an MOI of 4.2 PFU/cell in a 100-l inoculum. The inoculum was removed 2 h
postinoculation at either 32°C or 37°C. The cells were then washed once for 5
min with PBS and incubated at 32°C or 37°C, as indicated. Samples were har-
vested from the apical or basolateral surfaces of HAE for the determination of
8060 BARTLETT ET AL. J. VIROL.
virus titer or the amount of type I IFN produced. Apical samples were collected
by incubating the apical surface with 300 l of medium for 30 min at 32°C or
37°C, after which the remaining fluid was recovered. Basolateral samples were
collected directly from the basolateral compartment, and the volume removed
was replaced with fresh medium. Samples were stored at 80°C prior to analysis.
Histology and immunostaining of paraffin-embedded sections. HAE cultures
were fixed in 4% paraformaldehyde overnight and embedded in paraffin, and
5-m histological sections were prepared. Sections were then either stained with
hematoxylin and eosin for analysis by light microscopy or subjected to standard
immunofluorescence protocols. Briefly, sections were blocked with 3% bovine
serum albumin (BSA) in PBS (containing 1 mM CaCl2 and 1 mM MgCl2) and
incubated with primary antibodies diluted in 1% BSA. Primary antibodies in-
cluded a 1:4,000 dilution of rabbit anti-HPIV1 obtained from fluid present in
subcutaneous chambers of rabbits immunized with purified HPIV1 (hemagglu-
tination inhibition titer of 1:2,048), as described previously (9), and mouse
anti-acetylated alpha-tubulin (1:2,000; Zymed, San Francisco, CA). Secondary
antibodies used were fluorescein isothiocyanate-conjugated goat anti-rabbit im-
munoglobulin G (IgG) (Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA) and Texas Red-conjugated goat anti-mouse IgG (Jackson Immu-
noResearch Laboratories, Inc.). After a final wash, cells were overlaid with
VectaShield mounting medium (Vector Laboratories, Inc., Burlingame, CA).
Images were acquired using a Leica DMIRB inverted fluorescence microscope
equipped with a cooled color charge-coupled-device digital camera (Micro-
Publisher; Q-Imaging, Burnaby, British Columbia, Canada).
En face staining and confocal microscopy. HAE cultures were fixed overnight
in 4% paraformaldehyde and permeabilized with 2.5% Triton X-100. The cul-
tures were then blocked with 3% BSA–PBS, and apical surfaces were incu-
bated with primary antibodies diluted in 1% BSA. An additional primary anti-
serum used for en face staining was a rabbit anti-HPIV1 polyclonal antiserum
obtained by vaccinating whiffle ball-implanted rabbits. The primary rabbit anti-
HPIV1 serum was used at a 1:100 dilution, and the mouse anti-acetylated
alpha-tubulin antibodies were used at a dilution of 1:500. Secondary antibodies
were fluorescein isothiocyanate-conjugated goat anti-rabbit IgG and Alexa Fluor
594 goat anti-mouse IgG (Molecular Probes). Fluorescent confocal xy optical
sections were obtained using a Zeiss 510 Meta laser scanning confocal micro-
scope.
Type I IFN bioassay. The amount of type I IFN produced by infected HAE
was determined by an IFN bioassay according to previously published methods
(42). Briefly, clarified cell culture medium supernatants were treated at pH 2.0
for 24 h at 4°C to inactivate virus and acid-labile type II IFN, and the pH was
adjusted to 7.0 by the addition of 2 M NaOH. Type I IFN concentrations were
determined by measuring the restriction of replication of VSV-GFP on HEp-2
cell monolayers in comparison to a known concentration of a human IFN-
standard (Avonex; Biogen, Inc., Cambridge, MA). IFN- standard (5,000 pg/ml)
and IFN-containing samples were serially diluted 10-fold in duplicate in 96-well
plates of HEp-2 cells. After 24 h, the cells were washed and infected with
VSV-GFP at 6.5  104 PFU/well. Control cultures (no VSV-GFP, no IFN;
VSV-GFP, no IFN) were performed in quadruplicate on each plate. After an
additional 24 h, plates were read for total GFP expression on a Typhoon phos-
phorimager using a Typhoon 8600 scanner (Molecular Dynamics Inc., Sunnyvale,
CA) control program (fluorescence settings and 526-SP green fluorescein filter).
The dilution at which the level of GFP expression was approximately 50% of that
FIG. 1. rHPIV1 wt infects HAE cells, spreads throughout the culture, and replicates efficiently. HAE cells were mock infected or infected with
rHPIV1 wt at a low MOI (0.01 TCID50/cell). At days 1 to 7 p.i., cells were fixed and stained en face for HPIV1 antigen (green) (A), and virus titers
in the apical compartments were determined (B). Virus titers shown are the means of 3 to 11 cultures from a single donor  standard errors (SE).
The limit of detection is 1.2 log10 TCID50/ml, as indicated by the dashed line.
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in untreated cultures was determined as the end point. The end point of the
Avonex standard was compared to the end point of the unknown samples, and
IFN concentrations were determined and expressed as means  standard errors
(pg/ml). According to the manufacturers, using the World Health Organization
natural IFN- standard, the Avonex IFN- has a specific activity of approxi-
mately 1 IU of antiviral activity per 5 pg.
IFN mRNA qRT-PCR. The levels of IFN-	 and IFN- mRNA in HAE cul-
tures infected with HPIV1 wt or rHPIV1 mutants relative to those of mock-
infected cultures were determined by quantitative reverse transcription (qRT)-
PCR, as previously described (53). Briefly, total intracellular RNA was extracted
from cell cultures using the RNeasy total RNA isolation kit (Qiagen, Valencia,
CA). RNA was reverse transcribed using an oligo(dT) primer and reagents from
the Brilliant qRT-PCR kit (Stratagene, La Jolla, CA). The PCR primers and
Taqman probes used to detect human IFN-, two specific sets of human IFN-	,
and -actin were described previously (53). IFN-	 primer set 1 was specific for
human IFN-	1, IFN-	6, and IFN-	13, and IFN-	 set 2 was specific for human
IFN-	4, IFN-	5, IFN-	8, IFN-	10, IFN-	14, IFN-	17, and IFN-	21. Duplex
quantitative PCRs were performed to allow comparisons between IFN and the
housekeeping gene -actin. The probe for -actin was labeled with the reporter
dye 5-carboxyfluorescein at the 5 end, and all IFN probes were labeled with the
reporter dye 5-hexachloro-6-carboxy-fluorescein at the 5 end and Black Hole
Quencher 1 at the 3 end. Reaction mixtures contained a passive reference dye,
which was not involved in the amplification of IFN or -actin but was used to
normalize the probe reporter signals. Positive control curves were generated
using preparations known to contain high levels of IFN cDNA to ensure reaction
efficiency. Each reaction signal was corrected individually for the -actin signal.
In addition, signals from all reaction mixtures from virus-infected samples were
corrected against the signal generated in a mock-infected well, resulting in a
-actin-corrected measurement of expression over mock.
RESULTS
Characterization of rHPIV1 wt replication in HAE cultures.
It was previously shown that infection of HAE with RSV and
HPIV3 was specific to the ciliated cells of the surface epithe-
lium and was not associated with overt cytotoxicity, whereas
infection with influenza A virus resulted in the complete de-
struction of HAE cultures within 48 h (61, 67). In the present
paper, we characterized both the ability of HPIV1 wt to infect
HAE and the response to infection in these cultures. rHPIV1
wt efficiently infected HAE cells following apical inoculation
with rHPIV1 wt at a low MOI (0.01 TCID50/cell) (Fig. 1).
HPIV1 could be detected in HAE cells by en face immuno-
staining for HPIV1 antigen (Fig. 1A), and the increase in
apical wash titers from day 0 to day 1 postinfection (p.i.)
provided evidence of active replication and secretion of
rHPIV1 wt (Fig. 1). By day 3 p.i., virus had efficiently spread
throughout the culture, with significant numbers of cells stain-
ing positive for HPIV1 through day 7 p.i. (Fig. 1A). Virus titers
correlated with the numbers of cells staining positive for viral
antigen in the en face immunostaining (Fig. 1). rHPIV1 also
replicated efficiently in a single-step growth curve following
apical inoculation at a high-input MOI (5.0 TCID50/cell) (Fig.
2A). These growth curves were performed in the absence of
added trypsin (Fig. 1 and 2). Since HPIV1 typically requires
added trypsin for cleavage and infectivity when grown in cell
lines such as Vero cells, this suggests that a trypsin-like enzyme
capable of cleaving HPIV1 F is provided by HAE cultures.
Influenza virus, another virus requiring serine protease activity
at the apical surface for multicycle replication, also spread
efficiently in HAE models in the absence of exogenous trypsin
(33, 58). Attempts to isolate the required proteases that are
responsible for cleaving viral proteins present in such models
have identified some of these proteases (7), but there are most
likely many proteases present in the HAE. Viral titers during
infection were determined for both the apical and basolateral
compartments, representing virus shed into the airway lumen
and the serosal side of the epithelium, respectively. In general,
viruses causing disease limited to the respiratory tract release
virus via the apical surface only, whereas viruses released from
both the apical and basolateral surfaces are typical of viruses
that are able to spread systemically and cause disease in other
tissues. This was demonstrated here by comparing growth
curves for rHPIV1 wt to those for VSV (Fig. 2). As might be
expected for a virus that is strongly pneumotropic, rHPIV1 wt
was detected in apical washes but not in basolateral compart-
ments. In contrast, VSV, which is capable of systemic infection,
was released into both sites after basolateral inoculation (Fig.
2A and C).
The ciliated cells of the HAE have been shown to be major
targets for other respiratory viruses including influenza virus,
severe acute respiratory syndrome coronavirus, and paramyxo-
viruses such as RSV and HPIV3 (33, 51, 58, 66, 67). Similarly,
we show here that HPIV1 wt infects ciliated cells in HAE
FIG. 2. Comparison of single-cycle virus growth curves in HAE inoculated with rHPIV1 wt (A) or rHPIV1-CF170S (B) at an MOI of 5.0
TCID50/cell or with VSV (C) at an MOI of 4.2 PFU/cell at 37°C. Virus titers in the apical and basolateral compartments were determined at 8,
24, 48, and 72 h p.i. Virus titers shown are the means of cultures from two donors  SE, and the limit of detection is 1.2 log10 TCID50/ml.
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cultures, as observed by immunostaining of histological sec-
tions of HAE (Fig. 3A and C). HAE supports HPIV1 wt
infection, and the pattern of infection seemed to mimic that
observed for other paramyxoviruses such as RSV and HPIV3.
Therefore, HAE are a good model for studying HPIV1 infec-
tion. This model is further used here to characterize innate
host responses in human airway epithelial tissues to infection
and to determine the attenuation phenotypes of potential
HPIV1 vaccine candidates. In this study, infection with
rHPIV1 did not induce any gross changes in morphology or the
integrity of the epithelium or any other evidence of a cyto-
pathic effect within 48 h of inoculation in comparison to mock-
treated cells (Fig. 3B).
Induction of type I IFN during virus infection in HAE. The
HPIV1 wt C accessory proteins inhibit the type I IFN response
during infection, and this function is eliminated by a point
mutation, F170S, in the C ORF, which is present in all four
species of C protein, C, C, Y1, and Y2 (8, 59). In A549 cells,
type I IFN was detected during infection with rHPIV1-CF170S
but not rHPIV1 wt (59). We therefore compared levels of
replication and IFN induction by rHPIV1-CF170S and rHPIV1
wt in HAE. As was observed for HPIV1 wt, rHPIV1-CF170S
targeted ciliated cells in HAE (Fig. 3A). In addition, rHPIV1-
CF170S grew at least as efficiently as HPIV1 wt in a high-MOI
single-cycle growth curve (Fig. 2). However, although both
viruses reached similar peak titers, the kinetics of replication
were somewhat different. rHPIV1-CF170S reached a peak in
titer by 24 h p.i., at which point its titer was 100-fold higher
than that of rHPIV1 wt. In contrast, rHPIV1 wt titers rose
steadily until 72 h p.i. (Fig. 2). The differences in the kinetics of
virus replication between the two viruses in HAE correlated
with en face staining, which demonstrated that a higher pro-
portion of cells were positive for viral antigen following infec-
tion with rHPIV1-CF170S compared to that following infection
with rHPIV1 wt at both 24 and 48 h p.i. (Fig. 3C). This finding
was consistent for two independent donor sources of HAE
(data not shown). To investigate the initial higher replication
of rHPIV1-CF170S, we redetermined titers of mutant and wild-
type virus stocks for three different cell lines, LLC-MK2, A549,
and Vero cells. This showed that there were no cell line-
specific differences in titers or infectivities between the two
viruses. Furthermore, the ratios of infectious virus to hemag-
glutination titer were similar for the three viruses, indicating
that they were comparable in infectivity (data not shown).
Thus, the increased level of replication of the mutant virus did
not appear to be due to a difference in the amount of input
virus or its infectivity but may reflect a difference in the level of
gene expression (see Discussion).
Type I IFN could be readily detected following high-MOI
infection of HAE with rHPIV1-CF170S but not rHPIV1 wt (Fig.
4). Specifically, type I IFN secretion was detected in the apical
and basolateral compartments of rHPIV1-CF170S-infected
HAE by 48 h p.i., as determined by a type I IFN bioassay (Fig.
4A and B). In addition, significant IFN- mRNA expression
was detected as early as 24 h p.i. in this virus group, as deter-
mined by qRT-PCR (Fig. 4C), whereas IFN-	 mRNA was not
detected in any group (data not shown). VSV was used as a
positive control for IFN induction, and low levels of type I IFN
protein and IFN- mRNA were detected by 24 h following
VSV infection (Fig. 4). These results indicate that there is both
lumenal and basolateral/systemic release of type I IFN after
infection of HAE with rHPIV1-CF170S or VSV. The expression
of IFN- but not IFN-	 following infection with rHPIV1-
CF170S is consistent with our previous findings using A549 cells
and implies a strong block of IFN-mediated signaling (8, 59).
The lack of expression of IFN- by HAE cells following infec-
tion with rHPIV1 wt also is consistent with results with A549
cells but differs from previous results reported for MRC-5 cells
(8, 59). To investigate the role of the released type I IFN in the
FIG. 3. HPIV1 infection of ciliated cells without overt cytotoxicity.
HAE were inoculated with HPIV1 wt or rHPIV1-CF170S at an MOI of
5.0 TCID50/cell or were mock infected, and cells were processed at 24
and 48 h p.i. for histological analysis in cross section by immunofluo-
rescence (A) or hematoxylin and eosin staining (B) at 40 magnifica-
tion or stained en face (C). For histological immunofluorescence (A
and C), antibodies to HPIV1 (green) and acetylated alpha-tubulin
(red) were used to detect virus antigen and ciliated cells, respectively.
Scale bars represent 20 m (A and B) and 40 m (C).
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spread of HPIV1 in HAE, we next initiated infection at a lower
MOI (0.01 TCID50/ml) in longer-term infections.
Evaluation of the role of type I IFN in multicycle replication
of rHPIV1-CF170S in HAE. During natural HPIV1 infection,
infection is likely initiated at a low MOI via luminal inoculation
of the airways. Therefore, in order to mimic natural infection,
replications of HPIV1 wt and mutant virus were evaluated
using a multiple-cycle growth curve in HAE at 37°C at a low
MOI of 0.01 (Fig. 5). Both rHPIV1 wt and rHPIV1-CF170S
grew efficiently in HAE, reaching peak titers of 8.5 and 8.1
log10 TCID50/ml, respectively. The kinetics of replication and
extent of infection mirrored those observed in the high-MOI
FIG. 4. Comparison of the type I IFN response in HAE inoculated with rHPIV1 wt and rHPIV1-CF170S. HAE were inoculated with rHPIV1s
(MOI 
 5.0 TCID50/cell) or VSV (MOI 
 4.2 PFU/cell) or were mock infected, and levels of type I IFN mRNA and secreted protein were
quantitated at 8, 24, 48, and 72 h p.i. A type I IFN bioassay was used to quantitate levels of secreted type I IFN in the apical (A) and basolateral
(B) compartments compared to those of an IFN- standard. Type I IFN concentrations are expressed in pg/ml  SE and are the means of data
from duplicate cultures. The IFN- standard has a specific activity of approximately 1 IU of antiviral activity per 5 pg. The limit of detection for
type I IFN was 20.2 pg/ml. IFN- mRNA expression was quantitated by qRT-PCR (C). Total RNA was extracted from HAE at 8, 24, 48, and 72 h
p.i., and IFN- mRNA was measured by qRT-PCR using specific primers and Taqman probes that were previously described (53). For each
sample, the level of IFN- mRNA was relative to that of -actin and expressed as the increase compared to that for the mock-inoculated sample.
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growth curves (Fig. 2A and B and 3C). rHPIV1 wt reached a
peak titer at day 4 p.i., which remained at a plateau of about
8.5 log10 TCID50/ml until day 7 p.i. (Fig. 5). In comparison,
rHPIV1-CF170S reached a peak titer of 8.1 log10 TCID50/ml
much earlier, at day 2 p.i., and virus replication then dropped
dramatically by day 4 p.i. to plateau at 5.6 log10 TCID50/ml
(Fig. 5). In addition, determinations of type I IFN concentra-
tions in apical compartments by bioassay demonstrated no
detectable type I IFN during HPIV1 wt infection, whereas type
I IFN was detected from days 2 to 4 p.i. in cells infected with
rHPIV1-CF170S. Interestingly, the decrease in virus titer dur-
ing rHPIV1-CF170S infection followed the detection of type I IFN
secretion. We have shown that cells infected with rHPIV1-
CF170S are able to express type I IFN, and secreted IFN likely
acts on neighboring cells to establish an antiviral state. Since
HPIV1 is sensitive to an established type I IFN-induced anti-
viral state (59), these data suggest that type I IFN secretion
from virus-infected cells protected neighboring cells from virus
infection. This protection can be seen in the approximately
300-fold reduction of rHPIV1-CF170S replication in compari-
son to that of rHPIV1 wt (as indicated by the shaded area in
Fig. 5).
Replication of HPIV1 vaccine candidates in HAE. Since the
HAE culture model is a useful in vitro tool for evaluating
HPIV1 replication in a setting that closely resembles that of in
vivo replication in seronegative humans, this model could be
used for the preclinical evaluation of HPIV1 vaccine candi-
dates. In order to determine if the level of virus replication
in AGMs is reflected in the level of virus replication in HAE
cells, two attenuated HPIV1 mutants, rHPIV1-CR84G/170
HNT553ALY942A and rHPIV1-CR84G/170HNT553AL1710-11
(named according to their attenuating mutations) (see Mate-
rials and Methods), were chosen for study in the HAE model.
These viruses were chosen since they were previously charac-
terized in vivo (Table 1) (4) and are currently being considered
as live attenuated virus vaccine candidates for HPIV1. Clinical
trials using rHPIV1-CR84G/170HNT553ALY942A are currently
in progress. These viruses were previously shown to possess a
ts phenotype with in vitro shutoff temperatures (e.g., the lowest
temperature at which there is a 100-fold reduction in repli-
cation compared to that of the wild-type virus) of 38°C and
35°C, respectively, and both mutants were attenuated for rep-
lication in AGMs (4). Here, we evaluated their replication in
vitro in HAE. In order to simulate natural virus infection,
HAE were inoculated with the vaccine candidates at a low
MOI, and replication was compared to rHPIV1 wt replication
at 32°C and 37°C, temperatures indicative of those in the upper
and lower respiratory tracts, respectively (Fig. 6). Viral titers
determined in the apical washes over a 7-day period showed
that rHPIV1 wt replicated efficiently at both temperatures,
reaching peak titers of 8.5 and 9.1 log10 TCID50/ml, respec-
tively, by day 4 p.i. at 32°C and 37°C. However, both of the
FIG. 5. Virus replication and type I IFN production during multicycle growth curves in HAE inoculated with rHPIV1 wt and rHPIV1-CF170S
at an MOI of 0.01 TCID50/cell at 37°C. Virus titers (log10 TCID50/ml) (line graph) and type I IFN concentrations (pg/ml) (bar graph) in apical
washes were determined on each day from day 0 to day 7 p.i. The titers shown are means of data from duplicate donor cultures  SE. The limit
of detection for virus titers was 1.2 log10 TCID50/ml, and that for type I IFN was 31.1 pg/ml. The area shaded in gray represents the overall
difference in virus replication between rHPIV1 wt and rHPIV1-CF170S after day 2 p.i.
TABLE 1. Virus replication of HPIV1 wt and rHPIV1 mutants in AGMs and human airway epithelial cells
Virus
Lower respiratory tract of AGMsa Apical surface of HAE cells at 37°Cb
Mean peak virus titer
(log10 TCID50/ml)
Reduction in replication vs
HPIV1 wt (log10)
Virus titer on day 5
(log10 TCID50/ml)
Reduction in replication vs
HPIV1 wt (log10)
HPIV1 wt 3.9 8.6
rHPIV1-CF170S 2.7 1.2 5.8 2.8
rHPIV1-CR84G/170HNT553ALY942A 0.6 3.3 4.3 4.3
rHPIV1-CR84G/170HNT553AL1710-11 0.5 3.4 2.5 6.1
a Data were reported previously (4, 6).
b Virus titers were determined in low-MOI growth curves in HAE cells (Fig. 4 and 5).
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vaccine candidate viruses were severely restricted for replica-
tion in HAE and, unexpectedly, grew to higher titers at 37°C
than at 32°C (Fig. 6A and B). At 32°C, both viruses demon-
strated little to no replication, even though this temperature is
fully permissive for both viruses in monolayer cell lines, while
at 37°C, there was low-level replication, with mean peak titers
of 5.1 and 3.2 log10 TCID50/ml for rHPIV1-C
R84G/170
HNT553ALY942A and rHPIV1-CR84G/170HNT553AL1710-11,
respectively (Fig. 6B). Thus, the rHPIV1-CR84G/170HNT553A
L1710-11 virus demonstrated a higher degree of attenuation
than did rHPIV1-CR84G/170HNT553ALY942A. Since both vac-
cine candidates were more attenuated than the virus con-
taining only the CF170S point mutation, which was previously
shown to share the same phenotype as C170 (2, 59), these data
demonstrate that HAE cells are also sensitive to the attenua-
tion phenotype specified by other mutations, specifically, mu-
tations in the L gene. The attenuating effect of these mutations
was not revealed by any other in vitro method. Interestingly,
there was no type I IFN detected in the apical or basolateral
compartments of cultures infected with these viruses (data not
FIG. 6. The ability of HPIV1 vaccine candidates to replicate in HAE at 32°C and 37°C was determined by multicycle growth curves. HAE were
inoculated with rHPIV1 wt, rHPIV1-CR84G/170HNT553ALY942A, or rHPIV1-C
R84G/170HNT553AL1710-11 at an MOI of 0.01 TCID50/cell at 32°C and
37°C. Virus titers (log10 TCID50/ml) in apical and basolateral compartments were determined each day from days 0 to 7 p.i. The virus titers shown
are the means of data from triplicate donor cultures  SE for apical washes (samples from the basolateral compartments were negative for virus),
and the limit of detection is 1.2 log10 TCID50/ml.
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shown), which is likely due to the low levels of virus replication.
Based on these data, it is possible that these viruses will be
overattenuated in humans. However, the level of virus repli-
cation in the human upper respiratory tract in vivo remains to
be determined. These data correlate well with previous data
demonstrating the level of attenuation of these viruses in
AGMs (Table 1) (4) and suggest that the HAE model might be
a valuable preclinical tool. However, the ultimate validation of
the HAE model for HPIV1 will require the screening of a
larger sample of viruses with various levels of attenuation and
comparison of this information with similar data on their levels
of replication in seronegative humans.
DISCUSSION
HAE models provide useful tools for studying respiratory
viruses in vitro. These cell culture systems mimic many mor-
phological features of the human conducting airway epithe-
lium, permitting the study of virus-host interactions in a rele-
vant species as they occur at the site of virus infection. In this
study, we have evaluated the ability of HPIV1 wt to infect
HAE, and subsequently, we have determined a role for the
HPIV1 C proteins in the regulation of the innate immune
response in this system. HPIV1 wt readily infected HAE and
replicated to high titers but failed to induce the production of
type I IFN. The virus was released exclusively at the apical
surface of HAE, like many other respiratory viruses that do not
cause viremia (or spread systemically) (58, 66, 67). In contrast,
VSV, which is not a common human pathogen but which is
associated with systemic disease, albeit mild, in humans (30),
was released at both the apical and basolateral surfaces. Cili-
ated cells of the HAE have been shown to be the target for
many respiratory viruses including influenza virus, severe acute
respiratory syndrome coronavirus, and paramyxoviruses such
as RSV and HPIV3 (33, 51, 58, 66, 67). Furthermore, ciliated
cells were previously identified as being initiators of cytokine
secretion during RSV infection (35). We have shown here that
HPIV1 can efficiently infect HAE cells and that it specifically
targets ciliated cells. These studies indicate that the HAE
model is well suited to study the pathogenesis of HPIV1 mu-
tants. One such HPIV1 mutant, rHPIV1-CF170S, expresses de-
fective C proteins and induces moderate to high levels of type
I IFN, which in turn restricts the replication of rHPIV1-CF170S
in HAE. Thus, the HPIV1 C proteins are critical regulators of
the innate immune response in differentiated primary human
epithelial cells in vitro.
Most viruses, including HPIV1, are susceptible to antiviral
effects induced by IFN, and for this reason, many viruses have
evolved strategies to evade the IFN response (10, 18, 19, 59,
60). In humans, IFN- is the major type I IFN subtype pro-
duced, along with IFN-	1, as the first step in the IFN response
(29, 63). Following virus infection, cytoplasmic viral RNA is
recognized by host cell proteins such as the retinoic acid-
inducible gene I (RIG-I) protein (24, 44, 65). RIG-I subse-
quently associates with and activates mitochondrial antiviral
signaling (also known as IFN- promoter stimulator 1 protein
or virus-induced signaling adaptor protein) (48, 62). In epithe-
lial cells, viral double-stranded RNA is also recognized by
Toll-like receptor 3 (5) present in endosomes, resulting in the
activation of TRIF-mediated pathways (13, 49). The activation
of both the RIG-I and Toll-like receptor 3 pathways leads to
the activation of kinases (IKK-ε and TBK-1) that phosphory-
late IFN regulatory factor 3 (IRF-3), resulting in IRF-3 dimer-
ization and nuclear translocation. IRF-3 along with nuclear
factor B (NF-B) and ATF-2/c-Jun bind to the IFN- gene
promoter to activate IFN- transcription (64). IFN- is then
released from the cell and binds to type I IFN receptors on the
surface of virus-infected or neighboring cells to switch on the
Janus kinase/signal transducer and activator of transcription
(JAK/STAT) signaling pathway (18, 21, 28, 47, 57, 60). This
pathway culminates in the transcriptional induction of type I
IFN response genes, which comprise more than 300 genes that
are able to exert a broad range of antiviral, antiproliferative,
and immunomodulatory functions and include proteins such as
double-stranded RNA-activated protein kinase, 2,5-oligo-
adenylate synthetase, and the Mx proteins (28). In this way,
type I IFN can mediate the host immune response in virally
infected cells and establish an antiviral state in neighboring
uninfected cells in order to limit replication. The paramyxovi-
ruses express nonstructural accessory proteins that are able to
inhibit various stages of the type I IFN response. For example,
the V proteins of several parainfluenza viruses (e.g., HPIV2
and simian virus 5), RSV NS1 and NS2 proteins, and SeV and
HPIV1 C proteins have been shown to inhibit IRF-3 activation
(1, 6, 26, 53, 54, 59). In addition, the C proteins of SeV,
HPIV1, and HPIV3 and the V proteins of HPIV2 and simian
virus 5 have been shown to block the IFN signaling cascade by
various mechanisms, including STAT binding, the inhibition of
STAT activation, and STAT destabilization/degradation (8, 12,
14, 17, 20, 27, 31, 41, 56, 59).
The role of the HPIV1 C accessory proteins in inhibiting the
type I IFN response was recently characterized in vitro (8, 59);
however, it was uncertain whether these in vitro observations
would translate to similar functions in vivo. In HAE, both
rHPIV1 wt and rHPIV1-CF170S replicated efficiently and
reached similar mean peak titers. However, rHPIV1-CF170S
reached its peak titer by day 2, compared to day 4 for rHPIV1
wt, which was true at both high and low MOIs. Furthermore,
immunostaining of HAE infected at a high MOI also demon-
strated a clear quantitative difference between the viruses at
day 2 p.i., with many more cells staining positive in the
rHPIV1-CF170S-infected cultures than in the rHPIV1 wt-infected
cultures. Interestingly, a similar phenomenon was previously
observed in monolayer cultures with an SeV mutant containing
the same mutation in the SeV C proteins (15). The F170S
mutation in SeV had the effect of increasing gene transcription
fourfold compared to that of its parent virus, with correspond-
ing increases in RNA replication and virus replication (15).
This presumably accounts for the initial increased level of viral
replication and viral antigen synthesis (detected by immuno-
fluorescence) observed here for rHPIV1-CF170S in HAE cells.
The antiviral role of type I IFN became evident in HAE
infected at a low MOI, and the quantitative impact of the type
I IFN response was next assessed. HPIV1 wt virus replicated to
high titers, and type I IFN was not induced. The HPIV1 wt
virus titer persisted at a high level, presumably due to the
absence of IFN production in the cultures throughout the
duration of the study. In contrast, rHPIV1-CF170S replicated
efficiently until IFN was detected, and titers then decreased by
a factor of 100 to 1,000. While IFN is not the sole factor
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involved in viral clearance, the difference in replication be-
tween the two viruses in this model system is most likely due to
the induction of IFN in HAE infected with rHPIV1-CF170S, as
indicated by the shaded area in Fig. 5. It is likely that the type
I IFN secreted by virus-infected HAE cells is acting on the
neighboring uninfected cells to activate the JAK-STAT signal-
ing pathway and ultimately establish an antiviral state in these
cells by inducing the expression of type I IFN response genes.
This would lead to some level of inhibition of virus replication
and spread and would explain the decrease in virus titers that
we observed. Recently, STAT1 activation in mouse airway
epithelial cells was associated with the inhibition of cell-to-cell
spread of SeV and the protection of uninfected cells from
infection (50). Interestingly, rHPIV1-CF170S induced the ex-
pression of IFN- mRNA, while the expression of IFN-	 spe-
cies was below the level of detection. This confirms findings
observed for A549 cells and would be consistent with rHPIV1-
CF170S retaining the ability to inhibit IFN-mediated signaling
through the JAK/STAT pathway, which is necessary for the
expression of most of the species of IFN-	 and for the ampli-
fication of the IFN response.
The 100- to 1,000-fold difference in replication of rHPIV1-
CF170S and HPIV1 wt in HAE was similar to that observed in
the upper and lower respiratory tract of AGMs (Table 1),
suggesting that HAE provide a reliable model for the role that
type I IFN plays in restricting the replication of HPIV1 in vivo
(2). It is evident that IFN production was associated with a
reduction in virus replication; however, it was not sufficient to
completely inhibit virus growth. A recent study using influenza
A virus wild type and NS1-deficient viruses to infect murine
epithelial cells yielded similar quantitative effects (38). The
level of production of IFN- was significantly elevated during
infection with a human influenza A virus mutant expressing a
defective NS1 protein, a known inhibitor of RIG-I-mediated
type I IFN induction, compared to wild-type influenza A virus,
and IFN- production correlated with a reduction in the level
of replication of this virus in murine airway epithelial cells (38).
The role of the HPIV1 C proteins in inhibiting the type I IFN
response makes these proteins good targets for attenuating
viruses by mutagenesis, and A549 cells and HAE cultures ap-
pear to be suitable systems to study the effect of such mutations
on replication. Mutations of the C proteins are included in
current HPIV1 vaccine candidates (4).
The levels of replication of two HPIV1 vaccine candidates in
HAE were evaluated to determine whether the replication of
HPIV1 vaccine viruses in these cells might be predictive of
their level of replication in humans. Two live attenuated
vaccine candidates for HPIV1, namely, rHPIV1-CR84G/170
HNT553ALY942A and rHPIV1-CR84G/170HNT553AL1710-11 (4),
are being considered for evaluation in humans, and each mu-
tant contains mutations in C that specify the same IFN phe-
notype and attenuation phenotype as the CF170S point muta-
tion (2, 39, 59). In addition, both vaccine viruses contain a ts
attenuating mutation in the L polymerase gene that restricts
replication at 37°C. Both vaccine candidates replicate effi-
ciently at 32°C in Vero cells, the substrate for vaccine manu-
facture. We had anticipated that each vaccine candidate would
replicate efficiently at 32°C in HAE but would be restricted in
replication at 37°C due to the presence of the ts mutation.
Surprisingly, the viruses were completely attenuated for repli-
cation in HAE at 32°C following inoculation at a low MOI and
grew to very low levels at 37°C. The C and L gene mutations
may collaborate to restrict replication at 32°C by a mechanism
that is undefined but that can be addressed in HAE using
mutants in which the various attenuating mutations are segre-
gated. However, it is important that there was an additive
effect in the level of attenuation specified by the combination
of attenuating mutations in the P/C and L genes. This demon-
strates that HAE cells are sensitive to attenuation specified by
different mechanisms and underscores its validity as a tool for
the preclinical testing of viral vaccine candidates. How these
findings in HAE relate to replication in humans will be deter-
mined in clinical trials. Both vaccine candidates appear to be
safe for evaluation in humans based on their highly restricted
levels of replication in AGMs and HAE, but one or both
might be overattenuated for humans. rHPIV1-CR84G/
170HNT553ALY942A replicated to slightly higher titers at 37°C
than rHPIV1-CR84G/170HNT553AL1710-11 but was still signif-
icantly attenuated compared to rHPIV1 wt. IFN was not de-
tected in cells infected with these viruses, which is most likely
due to their highly restricted growth resulting in a poor induc-
tion of the innate immune response. Comparing data from this
in vitro study with those from previous in vivo studies, we have
shown that attenuation, i.e., restriction in replication in HAE,
correlates with the reduction in mean peak titers in AGMs
(Table 1) (2, 4). Although it is possible that these viruses will
be overattenuated in humans, we have selected the rHPIV1-
CR84G/170HNT553ALY942A candidate for further clinical eval-
uation since it is attenuated in AGMs, it replicates to some
extent in HAE, and it protects AGMs against challenge with
HPIV1 wt. In addition to evaluating the potential of this virus
as a vaccine, clinical trials will provide information on whether
virus replication in the HAE model correlates with the level of
attenuation of the virus in humans. A strong correlation would
highlight the usefulness of the HAE model as a preclinical
research tool and enable more efficient screening of HPIV1
and potentially other paramyxovirus vaccine candidates.
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